Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission
Fuente:
FierceBiotech
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.